Literature DB >> 3389047

Subcutaneous degradation of biosynthetic human growth hormone in growth hormone deficient patients.

J O Jørgensen1, A Flyvbjerg, T Lauritzen, H Orskov, J S Christiansen.   

Abstract

The aim of the present study was to look further into the question of local degradation of sc injected human GH in GH deficient patients. A comparison was made of serum GH levels after constant iv and sc infusion of the same amount of GH (33 ng.kg-1.min-1) in the same 9 GH deficient patients. A 3-h lag period was interposed between the iv and the sc infusion. Iv infusion was continued for 3 h. All 9 subjects subsequently received sc infusion for 19 h and five of them continued for additionally 24 h. The mean steady state serum GH level in the nine patients was 23.1 +/- 5.1 micrograms/l after iv and 6.8 +/- micrograms/l after sc administration (P less than 0.01). Extension of the sc infusion period in 4 of the subjects did not significantly alter the serum GH level (P less than 0.15), implying that a steady state was reached. The GH in the infusion system was stable throughout a 24-h period. We therefore conclude that sc injected GH is degraded locally to a substantial extent.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3389047     DOI: 10.1530/acta.0.1180154

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  4 in total

Review 1.  Current guidelines for adult GH replacement.

Authors:  Mauro Doga; Stefania Bonadonna; Monica Gola; Sebastiano Bruno Solerte; Giovanni Amato; Carlo Carella; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

Review 2.  Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration.

Authors:  Ninad Varkhede; Rupesh Bommana; Christian Schöneich; M Laird Forrest
Journal:  J Pharm Sci       Date:  2019-08-10       Impact factor: 3.534

3.  The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency.

Authors:  Y J Janssen; M Frölich; F Roelfsema
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

4.  Effects of recombinant human growth hormone in patients with severe sepsis.

Authors:  H J Voerman; R J van Schijndel; A B Groeneveld; H de Boer; J P Nauta; E A van der Veen; L G Thijs
Journal:  Ann Surg       Date:  1992-12       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.